Portland State University

PDXScholar
OHSU-PSU School of Public Health Faculty
Publications and Presentations

OHSU-PSU School of Public Health

2020

Validation of MicroRNA Biomarkers for Alzheimer’s
Disease in Human Cerebrospinal Fluid
Jack T. Wiedrick
Oregon Health & Science University

Jay I. Phillips
Oregon Health & Science University

Theresa A. Lusardi
Oregon Health & Science University

Trevor J. McFarland
Oregon Health & Science University

Babbet Lind
Oregon Health & Science University

Follow
this
andfor
additional
works
at: https://pdxscholar.library.pdx.edu/sph_facpub
See next
page
additional
authors
Part of the Medicine and Health Sciences Commons

Let us know how access to this document benefits you.
Citation Details
Wiedrick, Jack T.; Phillips, Jay I.; Lusardi, Theresa A.; McFarland, Trevor J.; Lind, Babbet; Sandau, Ursula K.;
Harrington, Christina A.; Lapidusa, Jodi A.; and multiple additional authors, "Validation of MicroRNA
Biomarkers for Alzheimer’s Disease in Human Cerebrospinal Fluid" (2020). OHSU-PSU School of Public
Health Faculty Publications and Presentations. 362.
https://pdxscholar.library.pdx.edu/sph_facpub/362

This Post-Print is brought to you for free and open access. It has been accepted for inclusion in OHSU-PSU School
of Public Health Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please
contact us if we can make this document more accessible: pdxscholar@pdx.edu.

Authors
Jack T. Wiedrick, Jay I. Phillips, Theresa A. Lusardi, Trevor J. McFarland, Babbet Lind, Ursula K. Sandau,
Christina A. Harrington, Jodi A. Lapidusa, and multiple additional authors

This post-print is available at PDXScholar: https://pdxscholar.library.pdx.edu/sph_facpub/362

HHS Public Access
Author manuscript
Author Manuscript

J Alzheimers Dis. Author manuscript; available in PMC 2019 August 08.
Published in final edited form as:
J Alzheimers Dis. 2019 ; 67(3): 875–891. doi:10.3233/JAD-180539.

Validation of MicroRNA Biomarkers for Alzheimer’s Disease in
Human Cerebrospinal Fluid
Jack T. Wiedricka, Jay I. Phillipsb, Theresa A. Lusardic, Trevor J. McFarlandd, Babett Linde,
Ursula S. Sandaub, Christina A. Harringtond, Jodi A. Lapidusa,f, Douglas R. Galaskog,
Joseph F. Quinne,h, Julie A. Saugstadb,*
aBiostatistics

& Design Program, Oregon Health & Science University, Portland, OR, USA

Author Manuscript

bDepartment

of Anesthesiology & Perioperative Medicine, Oregon Health & Science University,
Portland, OR, USA
cCancer

Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health &
Science University, Portland, OR, USA
dIntegrated

Genomics Laboratory, Oregon Health & Science University, Portland, OR, USA

eDepartment

of Neurology, Layton Aging and Alzheimer’s Center, Oregon Health & Science
University, Portland, OR, USA

fOregon

Health & Science University – Portland State University School of Public Health,
Portland, OR, USA

Author Manuscript

gDepartment
hPortland

of Neurosciences, University of California, San Diego, CA, USA

Veterans Affairs Medical Center, Portland, OR, USA

Abstract
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We previously discovered microRNAs (miRNAs) in cerebrospinal fluid (CSF) that differentiate
Alzheimer’s disease (AD) patients from Controls. Here we examined the performance of 37
candidate AD miRNA biomarkers in a new and independent cohort of CSF from 47 AD patients
and 71 Controls on custom TaqMan® arrays. We employed a consensus ranking approach to
provide an overall priority score for each miRNA, then used multimarker models to assess the
relative contributions of the top-ranking miRNAs to differentiate AD from Controls. We assessed
classification performance of the top-ranking miRNAs when combined with apolipoprotein E4
(APOE4) genotype status or CSF amyloid-β42 (Aβ42):total tau (T-tau) measures. We also assessed
whether miRNAs that ranked higher as AD markers correlate with Mini-Mental State Examination
(MMSE) scores. We show that of 37 miRNAs brought forth from the discovery study, 26 miRNAs
remained viable as candidate biomarkers for AD in the validation study. We found that
combinations of 6–7 miRNAs work better to identify AD than subsets of fewer miRNAs. Of 26
miRNAs that contribute most to the multimarker models, 14 have higher potential than the others
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to predict AD. Addition of these 14 miRNAs to APOE4 status or CSF Aβ42:T-tau measures
significantly improved classification performance for AD. We further show that individual
miRNAs that ranked higher as AD markers correlate more strongly with changes in MMSE scores.
Our studies validate that a set of CSF miRNAs serve as biomarkers for AD, and support their
advancement toward development as biomarkers in the clinical setting.

Keywords
Alzheimer’s disease; amyloid-β42; apolipoprotein E; biomarkers; cerebrospinal fluid; microRNA;
Mini-Mental State Examination; total tau
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Alzheimer’s disease (AD) is the most common form of dementia and the sixth-leading cause
of death in the United States [1]. Total costs for health care, long-term care, and hospice for
people with AD and other dementias were ~$259 billion in 2017 [2]. There is tremendous
effort by many investigators to discover preventative therapies for AD, and to develop
biomarkers that identify presymptomatic or preclinical cases of AD and monitor disease
progression. Cerebrospinal fluid (CSF) serves as an excellent biofluid for biomarker studies
in neuropathological diseases [3]. The most extensively studied CSF biomarkers include
amyloid-β42 (Aβ42), total tau (T-tau), and phospho-tau, which are diagnostically useful, but
do not track progression in the context of clinical trials [4]. However, the existence of
extracellular RNAs (exRNAs) in virtually all biofluids has offered new potential for
identifying diagnostic and/or prognostic markers for multiple human diseases [5].
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ExRNAs have been described in the literature for over 40 years. In 1978, Stroun et al.
showed that both DNA- and a pure RNA-nucleoprotein complex were released by human
and frog cultured cells, and the exRNA release was an active mechanism that is unrelated to
cell death [6]. The authors commented “whether exRNA is involved in intercellular transfer
of specific information or has only an unspecific stimulating function cannot be answered at
this stage”[6]. A decade later Benner proposed that “RNA as a short distance-short time
messenger seems to be a good match of chemistry and biological function” [7]. Benner’s
hypothesis arose from studies showing biological effects on extracellular actions by certain
ribonuclease homologs, which “implied that the substrate for extracellular RNases, exRNA,
must play a biological role in angiogenesis, neurological development, and other biological
processes” [7]. In 1999, Kopreski et al. found tyrosinase mRNA in the serum of patients
with malignant melanoma, even after the serum was filtered, indicating that the mRNA was
extracellular and that “exRNA in plasma from cancer patients associates with or is protected
in a multiparticle complex” [8]. Thus, exRNAs have great promise as biomarkers for
diseases, including neurodegenerative diseases [9].
We previously reported that miRNAs in CSF from living donors can serve as candidate
biomarkers for AD [10]. We identified a novel subset of 37 CSF miRNAs that were able to
distinguish AD patients from Controls in a discovery cohort, based on n = 1 technical
replicate/probe on the miRNA array. The 37 miRNAs include 20 that were verified by array
in our laboratory and 17 additional miRNAs that were brought forth as candidate markers.
J Alzheimers Dis. Author manuscript; available in PMC 2019 August 08.
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The validation studies were performed using a custom TaqMan Low Density qPCR array
comprised of n = 3 technical replicates/probe, in order to assess miRNA performance in a
new and independent cohort of CSF donors. We generated miRNA profiles for all cohort
samples, then used rigorous statistical approaches to rank the AD miRNA candidates. Our
studies validated that 26 of the 37 CSF miRNAs identified in the discovery studies can
differentiate AD patients from Controls, and combinations of miR-NAs increases
classification performance for AD. We identified 14 of the 26 miRNAs as high-ranking
markers. We then examined classification performance when the 14 miRNAs are added to
current AD markers, apolipoprotein E4 (APOE4) genotype status and CSF Aβ42:T-tau
measures. The validation of these CSF miRNAs in a new and independent cohort now
advances their consideration for development as biomarkers in the clinical setting, and for
their use in bioinformatic studies to identify potential novel gene targets relevant to AD.

Author Manuscript

MATERIALS AND METHODS
Analytic pipeline
Figure 1 illustrates the analytic pipeline flow for the AD miRNA biomarker validation
studies. The analytic pipeline included quality control processing of the miRNA array qPCR
data, followed by statistical analysis of the miRNAs to evaluate their ability to correctly
identify AD CSF in miRNA multimarker models, in combination with APOE4 genotype
status, and in combination with CSF Aβ42:T-tau measures. Further, we evaluated how the
miRNA markers correlate with disease severity as represented by Mini-Mental State
Examination (MMSE) scores.
Participants
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The CSF samples used for the validation studies were obtained from the University of
California, San Diego (UCSD) Alzheimer’s Disease Research Center (ADRC). All donor
procedures were approved by the UCSD Institutional Review Board (IRB 80012). All
participants provided written informed consent and underwent detailed evaluations
consisting of medical history, physical and neurological examinations, laboratory tests, and
neuropsychological assessments. Healthy Control subjects were recruited from the
community through public lectures, newsletters, and word of mouth. Some participants were
motivated by a family or spouse history of dementia, but others were simply motivated to
contribute to research, and we have previously reported that research lumbar punctures are
well tolerated and accepted even among healthy adults [11]. Cognitive health of the healthy
volunteers was ascertained with MMSE [12] and clinical interview, and the absence of
neurologic disease was confirmed by history and neurologic examination by a boardcertified neurologist. The donors were matched by age and sex, to the extent possible.
CSF collection
CSF was collected from donors using protocols established by ADRCs. Lumbar punctures
were done in the morning under fasting conditions, in the lateral decubitus position with a
24-gauge Sprotte spinal needle. The first 2 mL of CSF collected was used for clinical tests;
samples with > 500 Red Blood Cells/microliter were excluded from the study. Subsequent
10–20 mL of CSF is collected from each donor and gently mixed. The CSF samples were
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centrifuged at 2000 g for 10 min at room temperature, then aliquoted into polypropylene
tubes that include a subject number, but no other identifying information. The CSF aliquots
were flash frozen on dry ice and stored at −80°C.
APOE genotyping

APOE genotyping was performed at the UCSD ADRC using PCR restriction fragment
length polymorphism analysis, as described [13]. Genomic DNA was extracted and
amplified using forward primer: 5′-ACGCGGGCACGGCTGTCCAAGGA-3′; and reverse
primer: 5′-GCGGGCCCCGGCCTGGTACAC-3′. PCR products were Hha1 digested,
ethidium bromide stained, electrophoresed, and visualized by UV illumination.
CSF Aβ42 and T-tau measures
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Measurements of CSF Aβ42 and T-tau levels were performed at the UCSD ADRC using
enzyme-linked immunosorbent assays (ELISAs) as previously reported [14]. CSF Aβ 1−42
was measured using the Euroimmun ELISA kit (EQ 6521–9601-L, ADx Neurosciences,
Ghent, Belgium). CSF T-tau was measured using the ELISA kit (EQ 6531–9601-L, ADx
Neurosciences).
RNA isolation and qPCR
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We instituted safeguards to improve quality control of both the RNA isolations and the
qPCR arrays based on our AD miRNA discovery studies [10]. First, we included a pooled
CSF reference sample (RefStd) as a constant throughout the entire period of the qPCR
studies. The RefStd was comprised of CSF donated from healthy community volunteers that
was collected, pooled, and stored in 0.5 mL aliquots, as per the CSF collection protocol.
RefStds were included in batches of RNA isolations and run together with patient CSF
samples on the qPCR arrays to estimate and eliminate variance across processing batches
and individual array cards. Cost considerations precluded placement of a RefStd on every
card, so 13 RefStd samples were staggered at approximately even intervals throughout the
66-card study. Second, we included multiple miRNA controls on the arrays. Positive
controls (miRNAs unchanged between AD and Controls) were combined to form a complex
normalizer, while negative controls (miRNAs not found in CSF) were used to check the
validity of each array card. In our initial AD discovery studies, we used only U6 small
nuclear RNA (U6 snRNA) as a normalizer for the qPCR arrays [10]. For the validation
studies presented here, each custom array card contained 51 RNA probes: 37 candidate AD
miRNA biomarkers, 9 positive miRNA controls, U6 snRNA, and 4 miR-NAs not detected in
CSF (Supplementary Table 1A) at n = 3 technical replicates/miRNA probe in order to add
robustness to this study. Third, we imposed strict uniformity over the reagent manufacturing
lots: all kit and reagent lots were matched, with only two exceptions: one change in a lot of
RNA Clean & Concentrator kit™-5 (R1016, Zymo Research, Irvine, CA), and one change in
a lot of Reverse Transcriptase enzyme.
Total RNA was extracted from 0.5 mL of CSF using the mirVana™ PARIS™ Kit (AM1556,
(Thermo Fisher Scientific, Waltham, MA) as described [10]. The RNA samples were
concentrated using RNA Clean & Concentrator kit™-5 (R1016, Zymo Research). The
concentrated RNA samples were reverse transcribed using a custom MiRNA RT pool
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(4459652, Thermo Fisher Scientific) and TaqMan® MicroRNA Reverse Transcription Kit
(4366596, Thermo Fisher Scientific), then preamplified using a custom MiRNA PreAmp
pool (4459660, Thermo Fisher Scientific) and TaqMan® PreAmp Master Mix w/QRC
(4391128, Thermo Fisher Scientific). The pre-amplification products were diluted 1:4 in
RNase/DNase-free water, then 18 μL of diluted samples were mixed with TaqMan®
Universal PCR Master Mix II, no UNG (4440040, Thermo Fisher Scientific) and RNase/
DNase-free water to a final volume of 450 μL, loaded onto a custom TaqMan® Array Card
(4449140, Thermo Fisher Scientific) and amplified on a QuantStudio™ 12K Flex Real-Time
PCR instrument (4471089, Thermo Fisher Scientific) using QuantStudio™ 12K Flex
Software v1.2.2 (Thermo Fisher Scientific).
Preprocessing of Ct values
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The miRNA amplification data was then subjected to quality control filtering of the Ct
values using ExpressionSuite Software v.1.0.3 (Thermo Fisher Scientific). All further
processing and statistical analyses were conducted using Stata version 15.1 (StataCorp LLC,
College Station, Texas) and R version 3.4.1 (R Foundation for Statistical Computing; http://
www.r-project.org) software tools. We implemented biomarker acceptability rules to enable
go or no-go decisions for each candidate miRNA before assessing its predictive performance
in samples. First, we excluded miRNAs that did not amplify in at least 20% of the samples
to ensure that candidates had at least some biomarker potential. The 20% cutoff was
chosenbecause80%censoringwitha1:1case:control ratio means specificity can never exceed
40%, even with perfect sensitivity. We believed this would be a lower bound of usefulness
for a potential biomarker. Second, 2 of the 3 technical replicates/miRNA probe included on
the array needed to successfully amplify in the sample. Third, the data was filtered to ensure
good quality detection and to avoid false positives. Thus, we included amplifications with
median Ct values < 34, a cutoff chosen based on high replicate standard deviations for Cts >
34. Further, the amplifications had to have an AmpScore ≥1.0 and a CqConf ≥ 0.9. The
AmpScore indicates, for a given well, the rate of amplification in the linear region of the
response curve. The CqConf indicates the calculated confidence (between 0 and 1) for the
Cq/Ct value of the well. Thus, miRNAs that met these quality control standards were
considered for further analysis. We also required at least 90% attestation (the fraction of
samples that show evidence of expression for a given miRNA via their Ct values) across the
positive control miRNAs since these were used for normalization. Under these rules, we
retained 7 of the 10 positive controls, and 26 of the 37 possible miRNA biomarker
candidates (Fig. 1 and Table 2) identified in the discovery study for further analysis in this
validation study. All of the miRNA qPCR array data and donor-specific metadata have been
reposited in the exRNA Atlas [15] dataset Validation Study for Candidate AD miRNA
Biomarkers in Human CSF, #EXR-JSAUG1UH3001-ST that can be accessed via the
Datasets link at http://exrna-atlas.org/.
Batch correction and normalization
Since the CSF samples were measured over the course of many weeks, variation in ambient
temperature, machine calibration, and other minor, but uncontrolled and imperceptible
factors may arise. Thus, there is a need to ensure that card-to-card batch variations are
removed prior to analysis. To accomplish this, within each card, the Ct values for a sample
J Alzheimers Dis. Author manuscript; available in PMC 2019 August 08.
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were taken as the median of the miRNA values in the triplicate wells (n = 3 technical
replicates/miRNA probe); miRNAs with median value of 34 or larger were censored at 34,
which means that any miRNA with a Ct > 34 was considered to have expression too low for
reliable detection in the assay. These miRNAs were included in the analysis with an assigned
expression value of zero. The median Ct values were then corrected for day-to-day variance
in technical processing. Positive controls for the RefStds were treated as anchors and used to
align the array cards. With 13 RefStd samples included over the processing of 66 array
cards, and not appearing on every array card, we had to interpolate batch corrections for
cards that did not include a RefStd. These plausible card corrections were made by
averaging predictions from 5 models of batch differences: 1) the median of all probes; 2) the
mean of all positive control probes; 3) the mean and variance of the distribution of all
probes; 4) a linear trend to connect one RefStd anchor to the next in run-order sequence; and
5) a card median representing a random deflection from the sample mean of all card
medians. We then averaged these prediction values to align Ct values across all 66 cards.

Author Manuscript

Following batch correction, there is a need to normalize the Ct values by the overall miRNA
content of the sample, in order to ensure comparability of expression measurements. The
aligned Ct values were normalized relative to the mean of 7 “non-changing” positive
controls included on the arrays: 6 miRNAs (miR-1290, −204–5p, −30e-3p, −574–3p, −638,
−92a-3p), plus U6 snRNA (Supplementary Table 1). The normalization was done by
calculating a CSF sample-specific Ct value offset from a grand mean (i.e., the “subject
effect”) using a crossed random effects mixed model [16], and then subtracting this offset
from the measured Ct values for the sample. Similar to our discovery studies, we then
transformed the normalized Ct values onto an expression scale so that higher values indicate
relatively greater quantities of miRNA expression (the transformation is expression =
Ctnormmax –Ctnorm, where Ctnormmax is the largest non-censored normalized Ct value in
the data, rounded up to the nearest integer). Censored Ct values were assigned a value of
zero on this expression scale and included in the final analysis [10].
Biomarker relevance

Author Manuscript

We assessed the global relevance of the biomarker candidates by computing the multivariate
distance between observations using Mahalanobis distance. Mahalanobis distance is a way
of measuring the separation between a data point and the center of a group of data points
with respect to many variables, while accounting for their mutual correlations [17]. Thus,
samples similar in overall expression lie as close points in the space defined by the 26
miRNA values, while samples dissimilar in expression are widely separated in this space.
We calculated the distances of each of the AD and Control samples from the center of the
Controls using the covariance of the Controls as the scale in order to measure each sample’s
similarity to a typical Control sample. This same approach was used to verify
appropriateness of the positive control miRNAs as normalizers.
Biomarker importance ranking
The decision that a biomarker is important should be robust, so for greater assurance it is
essential to judge their importance in many different ways. To assess each candidate miRNA
as an AD biomarker, we examined: 1) the association between miRNA expression and AD
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status; 2) clear separation of miRNA expression between the AD and Control CSF; and 3)
complementarity of information when combined with other AD markers. Importantly, (1)
and (2) are complementary information about an individual marker, and (3) evaluates
miRNA value as members of larger biomarker groups that may provide synergistic
information regarding the disease state. Biomarker importance was assessed by 1) log-rank
tests [18] to account for censoring, 2) receiver operating characteristic (ROC) curves [19],
and 3) variable importance in random-forest classifiers using 4 different decision-tree
generation rules (CART [20], CFOREST [21], CHAID [22], BOOST [23]) to mitigate bias
in the importance estimate due to a particular decision rule.
Prioritization of AD miRNA biomarkers

Author Manuscript

We designed our analytical approach to elicit consensus across statistical methods and
prioritize candidate miRNAs as potential AD biomarkers. Each testing procedure generated
a ranking of the 26 validated miRNAs: different “judging” methods sorted the candidates
from best (1) to worst (26). Moreover, we incorporated information from our discovery
study in order to give due weight to our prior knowledge that certain candidates were likely
to fare better than others in validation testing. We did this by ranking the complete set of
candidates prior to doing any testing in the validation cohort, and we included this prior
ranking as a separate judge. Each judge independently ranks the miRNA markers, and then
the ranks for each miRNA marker are summed. This rank sum reflects our statistical
consensus opinion of a miRNA marker’s value. Significance of differences in rank sum were
assessed via permutation testing of the Skillings-Mack statistic [24].
Multimarker classification performance
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Although ranking and prioritization of individual miRNAs is an important first step in
understanding how the miRNAs may relate to AD status and progression, our ultimate goal
is to develop an AD classifier using the best available miRNA information. To be useful this
classifier needs to incorporate several different miRNAs into a “multimarker” model because
no single miRNA contains enough information about AD to enable reliable prediction. Thus,
assessing which miRNAs work well together and in what combinations is of key
importance. Multimarker classification performance was assessed by evaluating linear
combinations of all possible 1-, 2-, 3-, and 4-marker subsets of the 26 validated miRNAs.
We also carefully examined selected combinations of 5-, 6-, and 7-markers based on
performance in smaller sized subsets and/or rank sum. To benchmark classification
performance, we used a stepwise Bayesian model-averaging [23] procedure on the full set of
26 markers and selected 9 markers demonstrating robust contribution to all of the
multimarker models. The model-averaged area under the ROC curve (AUC) of this 9-marker
set (0.716) was used as a benchmark that any proposed model must beat. The subsets
described above yielded 76,867 unique models, whose classification (AUC) and model fit
(Akaike information criterion [AIC]) were calculated using logistic regression. We plotted
AIC versus AUC, denoting number of markers per model, and then superimposed a
nonlinear regression of AUC on AIC onto this plot to select top-performing combinations in
terms of classification, calibration, and parsimony. The combinations with highest AUC and
lowest AIC that rose above the benchmark were selected. The individual contribution to the
set of 93 top-performing models (which equated to the top 0.12% of the 76,867 models
J Alzheimers Dis. Author manuscript; available in PMC 2019 August 08.
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tested) was assessed for each miRNA by calculating the fraction of these models that the
miRNA was included in, and the size of the miRNA’s model-averaged coefficient.
Performance of AD miRNAs plus APOE4 genotype or CSF Aβ42:T-tau measures

Author Manuscript

Performance of the AD miRNA biomarkers was compared to the performance of the APOE4
genotype status and to the performance CSF Aβ42:T-tau measurements in the validation
cohort. Donors who were missing APOE4 genotype data (n = 5 Control, n = 2 AD) or
Aβ42:T-tau measures (n = 4 Control, n = 1 AD) were not included in this analysis so that all
models could be directly comparable on the same donor cohort (n = 60 Control, n = 41 AD).
We compared miRNA classification performance alone to miRNA performance after
combining APOE4 genotype or Aβ42:T-tau ratios with the miRNAs. We formed a k-nearestneighbor classifier (k = 3) so that all of the miRNA information would be used without
imposing any assumptions about either the relationships among the miRNAs or how they
contribute to AD classification. The k-nearest-neighbor classifier (k = 3) was based on
Canberra distance [25] between Mahalanobis-scaled miRNA expression values, setting prior
probabilities proportional to the AD and Control group sizes and breaking ties randomly.
Correlation of MMSE with higher-ranked miRNAs
We examined whether the correlation between MMSE scores and individual miRNA
expression levels would be larger for miRNAs that ranked higher as AD markers.
Correlation with MMSE was measured as the partial R2 statistic from a linear regression of
the individual miRNA expression on the MMSE score, adjusting for age and sex. The partial
R2 values were then compared to miRNA ranks using Spearman correlation.

Author Manuscript

RESULTS
Donor characteristics

Author Manuscript

The characteristics for the 71 Controls and 47 AD CSF donors evaluated in this validation
study are shown in Table 1. The donors were matched by sex to the extent possible, but there
was a somewhat higher percentage of females in the Control group (24 males:47 females;
33.8% males:66.2% females) compared to the AD patients (26 males:21 females; 55.3%
males:44.7% females). The donors were matched by age: mean age of healthy Controls was
72.72 ± 5.91, mean age of the AD patients was 73.13 ± 9.22. Controls were in good health
with a mean MMSE score of 29.13 ± 1.31, Clinical Dementia Rating (CDR) [26, 27] scores
of 0, and no evidence or history of cognitive or functional decline. AD patients were
diagnosed with probable AD according to the National Institute of Neurological Disorders
and Stroke–Alzheimer’s Disease and Related Disorders Association (NINDS-ADRDA)
criteria [28, 29], with a mean MMSE score of 22.06 ± 3.47, and CDR scores of 1–2. Of note,
the mean MMSE of the AD patients in the validation study (22.06 ± 3.47) was 4 points
higher than the mean MMSE in the discovery study (18.28 ± 6.4) [10], indicating that the
validation cohort reported here had milder dementia than the previously reported discovery
cohort. APOE genotyping was available for 111/118 donors (66 Controls and 45 AD): the
Control group had 62.12% with 0, 30.30% with 1, and 7.58% with 2 APOE4 alleles, while
the AD group had 35.56% with 0, 42.22% with 1, and 22.22% with 2 APOE4 alleles. As
expected, APOE4 genotype was over-represented in the AD group [30]. Most donors in the

J Alzheimers Dis. Author manuscript; available in PMC 2019 August 08.

Wiedrick et al.

Page 9

Author Manuscript

0 or 1 category of the APOE4 alleles had an APOE3 genotype, while only three donors had
an APOE 2,4 genotype (2 normal control males, 1 AD male). CSF Aβ42 and T-tau measures
were available for 106 of the 118 donors (64 Controls and 42 AD). The ratio of Aβ42:T-tau
in the Control group is 1.5 ± 0.8, while the AD group had a ratio of 0.6 ± 0.5. Thus, as
expected, the Aβ42:T-tau ratio decreased in the AD group [31].
Measures for validated AD miRNAs
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Table 2 lists the 37 candidate AD miRNA biomarkers tested in this validation study, and
shows the quantitative and statistical measures of the 26 miR-NAs that remained viable as
candidate biomarkers under our acceptability rules (Methods), as indicated by “Yes” in the
‘Viable’ column. Our analytic strategies focused on assessing these 26 viable miRNAs in
multimarker combinations, and we demonstrate that these miRNAs work together very well
to differentiate AD from Controls. First, we determined how well all 26 miRNAs can jointly
separate/classify AD from Control samples. Figure 2A plots the Mahalanobis distances of
AD and Control samples, showing how far each is from the center of the Controls in the
miRNA expression space. The individual Control samples (gray points) fall mostly at small
distances from the center (bottom of plot), while the AD samples (black points) fall mostly
at large distances (higher up the plot). Few Control samples are above the 80th percentile
(dashed) line, and few AD samples are below it. Using the Mahalanobis distance as a
classification index we attain AUC of 0.84, a value that serves as an estimate of the
maximum performance of the 26 viable miRNAs in this cohort. In contrast, the classification
potential of the positive control miRNAs in this cohort (Fig. 2B) shows that Control (gray)
and AD (black) samples are intermixed, and samples at larger distances come from both
groups. The 99.9th percentile (dashed) line contains nearly all samples and the AUC for the
positive control miRNAs is 0.54. This highlights the overall informativeness of the 26
miRNA candidates as AD biomarkers, as compared to steady-state positive control miRNAs.
Rankings of validated miRNAs
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We used seven independent “judges”, or statistical assessment criteria (described in
Materials and Methods) to characterize how well each of the 26 miRNAs work alone or in
combinations to correctly identify a CSF sample as AD or Control. Figure 3 shows the ranks
and rank sums of each of the 26 miRNAs according to these statistical assessments,
including the ranking based on prioritization in the discovery study [10]. Higher ranks are
indicated by smaller numbers, so that more highly ranked markers across all criteria have
lower rank sums. Two of the criteria (LogRank, ROC) assessed performance of individual
markers, while the remainder assessed classification performance of miRNAs in
combination. As shown via color-coding (red), miR-193a-5p, −597–5p, −195–5p, and
−378a-3p performed best and were also among the top discovery study performers. In
contrast, miR-484 and −584–5p were lower in the discovery prioritization, but performed
well here. However, our top discovery study performer, miR-142–3p, did not perform well
here. The latter two outcomes may reflect the difference in the average MMSE score
between the discovery and validation cohorts (4 points lower in the discovery cohort). For
example, miR-142–3p may preferentially signal laterstage AD and be an indicator of disease
progression.
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Most biomarkers reveal complementary information, and even modest miRNA combinations
showed greatly improved classification accuracy for AD compared to single miRNAs in our
discovery study [10]. As the best miRNA-based classifiers will necessarily be multimarker
combinations, we fit 76,867 multimarker models (described above), and selected 93 topperforming models for pairing good predictive power (high AUC) with good calibration (low
AIC). Figure 4 presents the ROC curves for all 93 top models, color-coded by size of the
model. Averages of ROC curves within each color are presented in bold. Combinations
consisting of 7 miRNAs (mean AUC = 0.796) are incrementally better at identifying AD
samples than combinations that consist of fewer miRNAs. Further, examples that contain as
few as 4 miRNAs attain a mean AUC > 0.72, the value we predicted in our prior study [10].
Some combinations of 6 and 7 miRNAs attain AUCs exceeding 0.80 (faint blue and orange
lines). Recalling that the classifier based on Mahalanobis distance in the complete 26-marker
space showed an AUC of 0.84 (Fig. 1A), we note that models comprising as few as onefourth of the markers approach that performance level. These values far exceed the best
performing individual miRNAs, underscoring the need for a multimarker-based approach to
AD prediction using miRNAs.
Top contributors to miRNA-based AD classifiers

Author Manuscript

After we identified the top-performing multimarker models, we next sought to determine
which of the 26 miRNAs contribute the most to performance in these models. In Fig. 5, we
plotted the percent contribution to the top 93 multimarker models (from Fig. 4) against the
consensus rank of each of the 26 validated miRNAs in the screening assessments (shown in
Fig. 3). Marker size is proportional to the magnitude of the model-averaged coefficient
estimate from the Bayesian model-averaging procedure (Materials and Methods,
Multimarker classification performance). The highest-ranked miRNAs markers tend to be,
but are not always, the most important contributors to the multimarker models. Our
exhaustive assessment of classification performance revealed that 14 of the 26 AD
biomarker candidates contributed strongly and in a mutually complementary and additive
manner to AD prediction across a broad range of model scenarios. These top 14 contributors
to miRNA-based classifiers are listed in Table 4.
APOE4 status improves miRNA classification performance

Author Manuscript

The APOE4 allele is a risk-factor gene as it increases a person’s risk of developing AD;
however, having an APOE4 allele does not guarantee that one will develop AD. Thus, many
researchers believe that APOE testing is useful for studying AD in large groups, but not for
determining an individual’s risk for AD. That said, given the known strong association
between APOE genotype and AD risk, we examined whether the genotype status was
redundant with the miRNA expression values, or whether it could add power to a general
miRNA-based classifier. We found that addition of APOE4 genotype status to the best 14
miRNAs (Table 4) increased the classification performance of the nearest-neighbor AD
classifier, particularly in the high-specificity range (Fig. 6). The AUC for the best 14
miRNAs independent of APOE4 is 0.820, but when APOE4 was added the AUC increased
to 0.856, a 4 point increase similar to that observed for parsimonious models in our

J Alzheimers Dis. Author manuscript; available in PMC 2019 August 08.

Wiedrick et al.

Page 11

Author Manuscript

discovery study [10]. It is worth noting that the AUC for APOE4 only is 0.637 in this cohort,
which is lower than the reported APOE4 performance (~0.67 [32]) and considerably lower
than performance in our discovery cohort (0.73). This is indicative of potential latent AD
cases among the current cohort Controls. Yet even in this low-powered setting, adding
APOE4 to the classifier yielded the same level of improvement, suggesting that the miRNA
expression phenotypes are not simply reflecting genetic risk; they also provide independent
power to differentiate AD from Controls.
Aβ42:T-tau improves miRNA classification performance

Author Manuscript

The CSF markers Aβ42 and tau (total and phospho) reflect AD pathology, and have high
accuracy to diagnose AD with dementia and prodromal AD in mild cognitive impairment
cases [33]. Therefore, we examined the performance of Aβ42 and T-tau, alone and in
combination with the miRNA biomarkers. Table 3 shows the diagnostic performance of CSF
Aβ42 and T-tau for 106 donors with available data, as well as the odds ratio for APOE4
positive status given a 1-standard-deviation change in the CSF marker (in the direction of
higher probability of AD) for the donors where both the Aβ42 and T-tau measures, and
APOE4 genotype status, were known. As expected [31], we found that both Aβ42 and T-tau
are good AD predictors of AD (AUC = 0.78, on par with any of the miRNA models), but the
Aβ42:T-tau ratio is dramatically better than either marker alone (AUC = 0.86) (Table 3). We
assessed the AUC of a full-information classifier using the top-contributing 14 miRNAs
(Table 4), which increased from 0.820 without Aβ42:T-tau to 0.903 with Aβ42:T-tau
(ΔAUC=0.08) (Fig. 7). Together, these data show that similar to the APOE4 results, the
miRNA information is not redundant with the Aβ42:T-tau ratio, but that it provides
independent power to differentiate AD from Controls. This finding importantly reveals that
CSF protein and miRNA measures provide complementary information about AD status.

Author Manuscript

CSF miRNAs and AD severity

Author Manuscript

Given that this validation cohort had diminished severity of dementia and somewhat reduced
classification performance of the miRNA panel compared to the discovery cohort, we
evaluated how the miRNA markers correlate with disease severity as represented by the
MMSE scores (Table 1). We found that the association (as measured by partial R2) between
MMSE scores and miRNA expression became stronger in higher-ranked miRNAs. For
example, our higher-ranked miRNAs, such as miR-193a-5p, have expression levels that
correlate more strongly with MMSE scores than our lower-ranked miRNAs, such as
miR-331–3p, which tend to show only weak correlation with MMSE at best. As shown in
Fig. 8, in general, the association between MMSE score and miRNA expression levels is
increasingly strengthened by an improvement in rank order, suggesting that these miRNAs
may also be able to signal disease progression in AD patients.

DISCUSSION
We previously discovered that CSF miRNAs can differentiate AD from Controls and
potentially serve as new biomarkers for AD [10]. Here we report results of validation studies
performed on 37 miRNAs identified in the discovery study, based on n = 1 technical
replicate/probe on the miRNA array. For the validation studies we assessed 37 miRNAs; 20
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that were verified by array in our laboratory, 17 additional that were brought forth as
candidate markers. The validation studies were performed using a custom array comprised
of n = 3 technical replicates/probe on the miRNA array, in order to assess miRNA
performance in a new and independent cohort of CSF donors. Our studies validate that 26 of
the previously identified CSF miRNAs continue to differentiate AD patients from Controls.
Further, combinations of miRNAs increases classification performance for AD. Based on
our multimarker modeling we identified 14 miRNAs that contributed strongly and in a
mutually complementary and additive manner to AD prediction (Table 4). In addition, we
confirm that a combination of new (miRNA) and existing (APOE4, Aβ42:T-tau) markers
increased classification performance, as we previously observed for APOE4 in our discovery
study [10]. In line with our results, hsalet-7b has been shown to work in combination with
either Aβ40 and Aβ42, or T-tau and p-tau, to increase the AUC relative to the independent
markers [34]. These findings strongly support that CSF miRNAs are not redundant with
APOE4 and Aβ42:T-tau, but instead offer additional diagnostic information. We also
demonstrate that our highest-ranked AD miR-NAs correlate with MMSE scores in AD,
which suggests these miRNAs have the potential to track disease progression and
consequently be of use in clinical trials.
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Previous multi-center AD biomarker studies have identified confounding factors including
sex, age, center of origin, and sample centrifugation status, which negated the utility of the
miRNAs to differentiate AD from controls [35]. To mitigate these effects, we selected sexand age-matched CSF samples and intentionally locked in the parameters for the validation
studies. The decision to maintain one technological methodology throughout our biomarker
studies was based on evidence of diminished reproducibility of results between expression
platforms, even when using the identical RNA for each platform [36]. This finding was also
consistent with our CSF analytic studies [37]. Thus, to maximize consistency within these
studies, we used the same vendor and the same miRNA probes throughout the discovery and
validation phases. Further, we enforced the use of identical manufacturing lots for kits and
reagents used throughout the experiments to minimize variation from sources unrelated to
the question of differentiating AD from controls. In doing so, we safeguard against spurious
associations due to measurement errors and batch effects, which is a strength of our study
that adds validity to the results.

Author Manuscript

Here we have validated that parsimonious combinations of 26 of the discovery miRNAs
continue to differentiate AD patients from controls. However, the performance of each
miRNA is not an exact match between the discovery and validation studies. There are two
experimental parameters that may account for this difference. First, U6 snRNA was used as
a normalizer for the discovery studies, but a combination of non-changing miRNAs
(including U6) served as a better normalizer for the validation studies. Second, donors in the
discovery cohort had more advanced dementia (MMSE: 18) relative to the validation cohort
(MMSE: 22), with a mean MMSE score 4 points lower in the discovery cohort. Thus, some
miRNAs may signal better in more advanced stages of AD.
Seven out of these 26 miRNAs (miR-125b-5p, −146a-5p, −146b-5p, −15b-5p, −195–5p,
−30a-3p, −328–3p) were previously identified by others as candidate biomarkers for AD
[38–41]. A previous study identified miR-27a-3p as a candidate biomarker that is decreased
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in the CSF of AD patients [42]; however, the miR-27a-3p finding was not replicated in our
studies. This difference is likely due to the use of different vendors and platforms
(TaqMan™ TLDAs versus Exiqon SYBR Green miRCURY LNA arrays) which can lead to
inconsistencies in results even when profiling an identical pool of RNA [36].

Author Manuscript

Our multimarker modeling identified certain miR-NAs that on their own are not interesting
as AD biomarkers and would likely have been excluded from earlier studies, but in the
proper context they strengthen a combined biomarker classifier (e.g., miR-331). In line with
our results, other studies show that multimarker modeling has strengths over single markers.
For example, a recent study of miR-NAs isolated from CSF extracellular vesicles found that
linear combinations of a subset of differentiating miRNAs (miR-16–5p, −125–5p, −451a,
−605–5p) increased classification performance between Controls and either young- or lateonset AD [43]. Two of these four miRNAs (miR-16–5p, −125–5p) were identified in our
discovery phase [10] and validated here (Table 2), supporting our observations that
measurable differences in AD patient miRNAs have utility as clinical biomarkers, and
miRNA combinations increase sensitivity and specificity compared to single miRNAs.
Our initial experiments with AD miRNA biomarkers focused on CSF, which directly bathes
the brain. We recognize that plasma is a more accessible biofluid, and we are encouraged by
pilot studies indicating that AD miRNA biomarkers are robustly detected in plasma, but
extensive plasma studies are beyond the scope of this report. We are currently designing
experiments to assess the performance of the AD miRNAs in a statistically powered study in
plasma samples that match this validation cohort.

Author Manuscript
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In summary, the validation studies presented here provide further, confirmatory evidence
that miRNA expression in CSF from living donors can distinguish AD patients from
Controls. Of 37 miRNAs from the discovery study, 26 miRNAs continue to differentiate AD
patients from Controls. Our exhaustive classification performance revealed that 14 of the 26
AD biomarker candidates contribute strongly and in a mutually complementary and additive
manner to AD prediction across a broad range of model scenarios. The miRNAs validated in
this study form a robust set of biomarkers that will now be further evaluated for use as
clinical biomarkers for AD. It is still premature to recommend a final list of miRNAs for
clinical practice. The miRNAs need to be evaluated for their performance in classifying mild
cognitive impairment and their presence in plasma (both discussed above); and we are
currently undertaking those studies. They will also be evaluated as to their specificity for AD
versus related neurodegenerative disorders and non-degenerative dementia, and examined in
longitudinal studies in individual patients to determine their efficacy as prognostic indicators
of AD. Moreover, we are studying the functional relationships between miRNAs and AD,
along the lines of recent reports investigating the role of miR-146a in inflammatory
pathways in brain [44] human brain cells [45], and AD transgenic mouse models [46]. The
validated miRNAs can serve to identify novel proteins and pathways linked to AD, and may
reveal novel targets for the diagnosis and/or treatment of AD. Thus, our validation of the
CSF miRNAs as biomarkers for AD in a new and independent cohort now supports their
advancement toward development and refinement as biomarkers in the clinical setting.
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Analytic pipeline for the AD miRNA biomarker validation studies. The analytic pipeline
included quality control processing of the miRNA qPCR data, followed by statistical
analysis of the miRNAs. First, we aligned and normalized the data, and then evaluated the
classification performance of miRNA expression values in multimarker models, in
combination with APOE4 genotype status and CSF Aβ42:T-tau measures. Further, we
examined the correlation of MMSE with miRNA expression values by miRNA rank.
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Fig. 2.
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A) Overall classification potential of biomarker candidate miRNAs. Mahalanobis distances
of AD and non-AD (Control) samples from the center of the Controls in the miRNA
expression space show that the Control (gray) points fall mostly at small distances from the
center (bottom of the plot area), while the AD (black) points fall mostly at large distances
(higher up in the plot). Using the distances to classify samples gives an AUC of 0.84. B)
Overall classification potential of positive control miRNAs. Mahalanobis distances
calculated from the center of the Control group with respect to the positive control miRNAs
show that the Control (gray) and AD (black) samples are randomly intermixed, and samples
at larger distances come from both groups. Using these distances to classify samples gives
an AUC of only 0.54. For the Mahalanobis distance calculations, we imputed values > 34 Ct
for censored observations using predictions from a tobit regression model [47] in order to
jitter the censored values appropriately. %ile, percentile.
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Rank plot of the 26 validated AD miRNA biomarkers. The plot shows the ranks and rank
sums of each of the 26 miRNAs according to seven independent “judges”: six statistical
assessment criteria, plus the rank of the miRNA in the prior discovery study [10]. The ranks
of the individual table cells are color-coded along a red-blue color ramp to visually assess
consistency of rankings and to identify higher ranking “hot” (red) and lower ranking “cool”
(blue) miRNA candidates.
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Fig. 4.
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Classification accuracy for miRNA combinations. The plot depicts the average receiver
operating characteristics (ROC) for the 93 best multimarker models of the validated
miRNAs. The faint lines are the individual ROC curves for the top-multimarker models
(color coded based on the number of miRNAs that contributed to the model). Bold solid
lines are the empirical averages of the individual ROC curves. Dashed curves are binormal
estimates of the average. The mean area under the curve (AUC) for the averaged ROC
curves are presented. Note that some of the individual ROC curves generated from 6
miRNAs (faint orange lines) or 7 miRNAs (faint blue lines) have AUCs that exceed 0.80.
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MiRNA percent contribution to the top multimarker models against the consensus rank. The
figure shows how our statistical consensus ranking relates to marker contribution in
multimarker models. For each of the 26 miRNAs the percent contribution to a multimarker
model is plotted against the consensus rank in the screening assessments. Contribution
percentage is based on presence in the top 0.12% (93/76867) of multimarker models. Marker
size is proportional to the magnitude of the marker’s model-averaged coefficient estimate.
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Fig. 6.
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APOE4 plus miRNAs improves classification performance over the best-possible miRNAsonly model. The plot depicts the receiver operating characteristics (ROC) curves for a
multimarker model that includes the best miRNAs (dashed line), APOE4 only (dark gray
line), and all 14 miRNAs plus APOE4 (solid line). The area under the curve (AUC) for the
best 14 miRNAs increases from 0.820 without APOE4 to 0.856 with APOE4 (ΔAUC=0.04).
The AUC estimates are based on k-nearest-neighbor nonparametric classifiers that
incorporate information from the top 14 miRNAs found to contribute to the best multimarker
models (Table 4).
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Fig. 7.
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Aβ42:T-tau plus miRNAs dramatically improves classification performance over the bestpossible miRNAs-only model. The plot depicts the receiver operating characteristics (ROC)
curves for a multimarker model that includes the “best” (i.e., top-contributing) 14 miRNAs
(dashed line), Aβ42:T-tau only (dark gray line), and the best 14 miRNAs plus Aβ42:T-tau
(solid line). Area under the curve (AUC) increases from 0.820 for the miR-NAs without
Aβ42:T-tau to 0.903 with Aβ42:T-tau (ΔAUC = 0.08). The AUC estimates are based on knearest-neighbor nonparametric classifiers that incorporate information from the top 14
miRNAs found to contribute to the best multimarker models (Table 4).
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Fig. 8.
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Correlation of MMSE with top 14 miRNAs found to contribute to the best multimarker
models. The X-axis is the rank order of the 14 higher-ranked miRNAs, and their respective
single-marker AUCs are shown in the labels. The Y-axis is the squared partial correlation
(i.e., partial R2) of MMSE with the miRNA expression in patients, adjusted for age and sex.
The figure shows that individual miRNAs that ranked higher as AD markers (Table 4)
correlate more strongly with changes in MMSE score. The Spearman correlation between
partial R2 and miRNA rank was 0.82.
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28.88 ± 1.62
29.26 ± 1.11
29.13 ± 1.31

Male

Female

Total

64

%

100.00

22.22

42.22

35.56

42

0.44 ± 0.05

0.6 ± 0.5

689.4 ± 335.1

305.5 ± 154.8

Mean ± SD

45

10

19

16

Count

Age and MMSE values represent data at the time of CSF collection.

Total

#

1.5 ± 0.8
1.22 ± 0.10

392.2 ± 201.1

T-tau

mean(Aβ42):mean(T-tau)

479.0 ± 210.1

Aβ42

Aβ42:T-tau

Mean ± SD

100.00

7.58

30.30

62.12

Aβ42:TAU

66

5

2

^

20

1

Total

41

0

22.06 ± 3.47

21.05 ± 3.38

22.88 ± 3.37

Mean ± SD

73.13 ± 9.22

73.71 ± 10.05

72.65 ± 8.67

Mean ± SD

47

21 (44.7%)

26 (55.3%)

AD

†

%

†

100.00

13.51

35.14

51.35

106

−0.78 ± 0.11

−0.9 ± 0.9

297.3 ± 385.7

−173.5 ± 258.1

Difference ± SDboot

111

15

39

57

Count

−7.06 ± 3.67

−8.22 ± 3.48

−5.99 ± 3.68

Difference ± SDboot

72.88 ± 7.37

72.31 ± 7.21

73.66 ± 7.60

Mean ± SD

118

68 (57.6%)

50 (42.4%)

All

SDboot, standard deviation of differences between randomly selected AD and CONTROL individuals based on 100,000 bootstrap samples.

†

*

Mean ± SD

MMSE*

%

72.72 ± 5.91

Total

Count

71.68 ± 5.52

Female

APOE4 ALLELES

74.75 ± 6.24

Male

71

Total
Mean ± SD

47 (66.2%)

Female

AGE*

24 (33.8%)

CONTROL

Male

SEX

Donor characteristics. The table includes the number, sex, age, and MMSE for the 118 Control and AD patients evaluated in this validation study. APOE4
genotype status was available for 111 of the CSF donors, while Aβ42 and T-Tau measures was available for 106 of the CSF donors evaluated in the study
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For available donor samples; Aβ42 and T-tau measures for n = 7 Control and n = 5 AD were not available.

#

For available donor samples; genotyping data for n = 5 Control and n = 2 AD were not available.
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miR-125b-5p

miR-1291

miR-140–5p

miR-142–3p

miR-143–3p

miR-145–3p

miR-145–5p

miR-146a-5p

miR-146b-5p

miR-15b-5p

miR-16–5p

miR-193a-5p

miR-195–5p

miR-19b-3p

miR-202–3p

miR-223–3p

miR-24–3p

miR-26b-5p

miR-27b-3p

miR-28–3p

miR-29a-3p

miR-30a-3p

0005881

0000431

0000434

0000435

0004601

0000437

0000449

0002809

0000417

0000069

0004614

0000461

0000074

0002811

0000280

0000080

0000083

0000419

0004502

0000086

0000088

Name

miRBase

0000423

MIMAT
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Yes

Yes

Yes

No

No

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Yes

Viable

9.5

11.5

17

8

19

3

20

4

11.5

21

17

14

17

7

1

14

9.5

Disc

0.55

0.91

0.58

1.00

0.06

0.12

0.78

0.22

0.53

0.30

0.83

0.24

0.72

0.80

0.93

0.18

0.55

0.50

0.52

0.53

0.55

0.59

0.53

0.62

0.52

0.55

0.57

0.56

0.51

0.55

0.50

0.57

0.52

AUC

p-value
0.89

ROC

Log-Rank

21

8

14

25

17

3

12

4

24

7

11

10

16

20

22

15

13

CART

11

21

17

20

8

7

14

2

26

9

19

12

24

13

23

10

22

CFOREST

Rank

11

13

10

19

5

12

17

3

25

24

18

9

23

8

7

21

4

CHAID

10

22

9

24

4

8

25

3

19

7

17

6

16

20

18

14

13

BOOST

50

43

39

83

99

93

31

71

84

31

79

84

71

36

81

36

69

Control

53

43

43

81

100

96

32

74

89

23

72

94

74

32

81

23

68

AD

% Detected

1.28

1.15

1.21

1.06

1.15

1.23

1.06

1.39

0.96

0.96

1.27

0.86

1.10

1.20

1.02

1.17

1.17

Log2

(0.96,1.70)

(0.86,1.56)

(0.98,1.51)

(0.75,1.49)

(0.90,1.48)

(0.86,1.77)

(0.83,1.36)

(1.03,1.87)

(0.61,1.51)

(0.76,1.22)

(0.91,1.79)

(0.60,1.24)

(0.84,1.43)

(0.96,1.50)

(0.72,1.44)

(0.89,1.54)

(0.81,1.67)

95% CI

Fold Change

Quantitative and statistical measures of the 37 candidate AD miRNA biomarkers tested in the validation study. The list shows the MIMAT accession
number for each miRNA. The 26 miRNAs that remained viable as candidate AD biomarkers are indicated by “Yes” in the ‘Viable’ column. The ‘Rank’
columns indicate the judges used to rank-sort the miRNAs, and include the ranking of each miRNA in the discovery (Disc) study. Two judges (LogRank,
ROC) assessed performance of individual miRNA markers, while the remainder assessed classification performance of miRNAs in combination. The % of
miRNAs detected in each diagnostic group and the fold change for each miRNA are also listed
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Yes
Yes
Yes

miR-331–3p
miR-340–5p
miR-365a-3p
miR-378a-3p*
miR-378a-3p**
miR-484
miR-519b-3p
miR-520b-3p
miR-532–5p
miR-584–5p
miR-590–5p
miR-597–5p
miR-603

0000760
0004692
0000710
0003379
0000732
0002174
0002837
0002843
0002888
0003249
0003258
0003265
0003271

No

miR-328–3p

0000752

No

Yes

No

Yes

Yes

No

No

Yes

No

Yes

Yes

miR-30d-5p

0000245

Name

Probe designed to nt 1–22 of miR-378a-3p.

**

2

24.5

24.5

24.5

6

5

24.5

22

14

Disc

Probe designed to nt 1–21 of miR-378a-3p,

*
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Viable

0.56

0.22

0.85

0.16

0.31

0.11

0.69

0.71

0.62

0.59

0.54

0.60

0.58

0.57

0.56

0.53

0.55

AUC

p-value

0.72

ROC

Log-Rank

5

1

19

6

9

2

23

18

26

CART

4

1

18

3

6

5

16

15

25

CFOREST

Rank
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miRBase

1

2

20

6

16

14

26

22

15

CHAID

1

2

23

12

15

5

21

26

11

BOOST

97

77

26

89

87

67

56

23

60

Control

94

83

28

91

89

81

55

19

66

AD

% Detected

1.45

1.23

1.13

1.21

1.31

0.97

0.90

1.20

0.95

Log2

(0.98,2.15)

(0.93,1.64)

(0.89,1.43)

(0.89,1.64)

(0.97,1.79)

(0.68,1.37)

(0.69,1.16)

(0.93,1.54)

(0.69,1.32)

95% CI

Fold Change
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0.782

0.861

T-tau

Aβ42:T-tau
<0.83

>836

<360

Best Cutoff

81.0%

73.8%

78.6%

Sensitivity

79.7%

73.4%

64.1%

Specificity

2.81

3.97

1.62

SDΔ odds ratio for APOE4*

For reduced cohort not missing APOE genotyping: 60 Control and 41 AD.

*

0.782

AUC*

Aβ42

Marker

from a logistic regression of APOE4 genotype status on the standardized values of the marker)

also lists the odds ratio for APOE4 positive status given a 1-standard-deviation change in the CSF marker (in the direction of higher probability of AD)
for the 101 donors where both the Aβ42:T-tau and the APOE4 genotype status were known. (Odds ratios were calculated as the exponentiated coefficient

CSF Ab42 and T-tau measures. The table lists the diagnostic performance of CSF Aβ42 and T-tau for the 106 donors with available measures. The table
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miR-584–5p

miR-146a-5p

miR-597–5p

miR-30a-3p

miR-378a-3p*

miR-365a-3p

miR-484

miR-193a-5p

miR-140–5p

miR-146b-5p

miR-223–3p

0003249

0000449

0003265

0000088

0003379

0000710

0002174

0004614

0000431

0002809

0000280

miR-331–3p

0000760

miR-19b-3p

miR-15b-5p

0000417

0000074

miRBase Name Name

MIMAT

9.7

9.7

12.9

14.0

22.6

32.3

45.2

46.2

48.4

49.5

62.4

64.5

75.3

97.8

% Contribution to Multimarker
Models Models

0.18

−0.01

−0.04

0.03

0.02

−0.03

0.08

0.06

0.03

0.05

0.08

0.07

−0.01

−0.14

Model-Averaged Logit
Coefficient

0.45

0.27

0.36

0.34

0.29

0.33

0.56

0.44

0.28

0.39

0.46

0.42

0.26

0.59

Bayesian Posterior Model
Inclusion Probability

8

16

11

1

6

21

4

10

2

9

5

3

24

12

Overall Rank in Screening
Assessments

MiRNAs that contributed strongly and in a mutually complementary and additive manner to AD prediction based on multimarker modeling, sorted based
on their percent (%) contribution to multimarker models
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